{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-063202","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2026-05-18T20:15:33+00:00","discovered_at":"2026-05-18T20:17:00.211735+00:00","generated_at":"2026-05-18T21:13:30.082228+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cellectar director Loren not standing for reelection; Nantahala analyst Gu appointed to board","bullets":["Dr. Stefan Loren will not stand for reelection at 2026 annual meeting; no disagreement with the company.","Loren enters consulting agreement: $15,000/quarter for one year, plus 15,000 stock option grant.","Andrew Gu appointed as Class III director on May 18, 2026, selected by Nantahala Capital Management.","Gu is an analyst at Nantahala, focuses on biotech; he joins the Audit Committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-063202","json":"https://secwatch.observer/filing/0001104659-26-063202.json","markdown":"https://secwatch.observer/filing/0001104659-26-063202.md","text":"https://secwatch.observer/filing/0001104659-26-063202.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926063202/0001104659-26-063202-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926063202/tm2614924d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T21:13:30.082228+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3984c374ea","claim":"Stefan D. Loren departed as Class III Director at Cellectar Biosciences, Inc..","evidence_excerpt":"On May 17, 2026, Stefan D. Loren, Ph.D. notified the board of directors (the “Board”) of Cellectar Biosciences, Inc. (the “Company”), that he does not intend to stand for reelection as a Class III director at the upcoming 2026 annual meeting of the stockholders of the Company (the “Annual Meeting”), at which time his current term as a director will expire.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926063202/0001104659-26-063202-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"not standing for reelection"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"},{"claim_id":"f96a100006","claim":"Andrew Gu was appointed as Class III Director at Cellectar Biosciences, Inc..","evidence_excerpt":"On May 18, 2026, the Board appointed Mr. Gu to serve as a member of the Board as a Class III director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926063202/0001104659-26-063202-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}